Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Sonnet BioTherapeutics (NASDAQ:SONN) with a $30 price target.
May 28, 2024 | 10:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on Sonnet BioTherapeutics with a $30 price target.
The reaffirmation of a Buy rating and a $30 price target by Chardan Capital is likely to positively impact Sonnet BioTherapeutics' stock price in the short term as it signals confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100